When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OVID - Enrollment underway in late-stage study of Ovid's gaboxadol in Angelman
Ovid Therapeutics Inc.
The first patient has been randomized in a Phase 3 clinical trial, NEPTUNE, evaluating Ovid Therapeutics' (OVID-3.2%) lead candidate OV101 (gaboxadol) in patients with an inherited nervous system disorder called Angelman syndrome.
More news on: Ovid Therapeutics Inc., Healthcare stocks news,